WO2003095633A3 - Verfahren zur herstellung von zellen mit erhöhtem entwicklungspotential - Google Patents

Verfahren zur herstellung von zellen mit erhöhtem entwicklungspotential Download PDF

Info

Publication number
WO2003095633A3
WO2003095633A3 PCT/DE2003/001516 DE0301516W WO03095633A3 WO 2003095633 A3 WO2003095633 A3 WO 2003095633A3 DE 0301516 W DE0301516 W DE 0301516W WO 03095633 A3 WO03095633 A3 WO 03095633A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
production
development potential
increased development
activated
Prior art date
Application number
PCT/DE2003/001516
Other languages
English (en)
French (fr)
Other versions
WO2003095633A2 (de
Inventor
Ulf R Rapp
Bernd Neufeld
Original Assignee
Ulf R Rapp
Bernd Neufeld
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ulf R Rapp, Bernd Neufeld filed Critical Ulf R Rapp
Priority to AU2003227513A priority Critical patent/AU2003227513A1/en
Priority to US10/513,500 priority patent/US20060094115A1/en
Priority to EP03724890A priority patent/EP1501920A2/de
Publication of WO2003095633A2 publication Critical patent/WO2003095633A2/de
Publication of WO2003095633A3 publication Critical patent/WO2003095633A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die Erfindung betrifft ein Verfahren zur Herstellung von Zellen mit erhöhtem Entwicklungspotential aus Zellen, welche einem Organismus entnommenen sind, wobei die entnommenen Zellen in vitro kultiviert werden und wobei eine native nukleäre nicht aktivierte MAPKAP Kinase der kultivierten Zellen aktiviert oder eine aktivierte MAPKAP Kinase dem Zellkern der Zellen zugeführt wird.
PCT/DE2003/001516 2002-05-07 2003-05-07 Verfahren zur herstellung von zellen mit erhöhtem entwicklungspotential WO2003095633A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003227513A AU2003227513A1 (en) 2002-05-07 2003-05-07 Method for the production of cells with increased development potential
US10/513,500 US20060094115A1 (en) 2002-05-07 2003-05-07 Method for the production of cells with increased development potential
EP03724890A EP1501920A2 (de) 2002-05-07 2003-05-07 Verfahren zur herstellung von zellen mit erhöhtem entwicklungspotential

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10220480A DE10220480C1 (de) 2002-05-07 2002-05-07 Verfahren zur Herstellung von Zellen mit erhöhtem Entwicklungspotential
DE10220480.2 2002-05-07

Publications (2)

Publication Number Publication Date
WO2003095633A2 WO2003095633A2 (de) 2003-11-20
WO2003095633A3 true WO2003095633A3 (de) 2004-03-04

Family

ID=27740750

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2003/001516 WO2003095633A2 (de) 2002-05-07 2003-05-07 Verfahren zur herstellung von zellen mit erhöhtem entwicklungspotential

Country Status (5)

Country Link
US (1) US20060094115A1 (de)
EP (1) EP1501920A2 (de)
AU (1) AU2003227513A1 (de)
DE (1) DE10220480C1 (de)
WO (1) WO2003095633A2 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034137A2 (en) * 1996-03-12 1997-09-18 Smithkline Beecham Corporation Methods of the identification of pharmaceutically active compounds
EP1109918B1 (de) * 1998-06-24 2006-10-04 University of Dundee Mitogen- und stress-aktivierte proteinkinasen, die zwei kinase domänen enthalten, und deren verwendungen
US6087168A (en) * 1999-01-20 2000-07-11 Cedars Sinai Medical Center Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
ALLEN M ET AL: "Deficiency of the stress kinase p38alpha results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells.", THE JOURNAL OF EXPERIMENTAL MEDICINE. UNITED STATES 6 MAR 2000, vol. 191, no. 5, 6 March 2000 (2000-03-06), pages 859 - 870, XP002249029, ISSN: 0022-1007 *
ARTHUR J S C ET AL: "MSK1 is required for CREB phosphorylation in response to mitogens in mouse embryonic stem cells", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 482, no. 1-2, 29 September 2000 (2000-09-29), pages 44 - 48, XP004337618, ISSN: 0014-5793 *
BAKIN ANDREI V ET AL: "p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration.", JOURNAL OF CELL SCIENCE. ENGLAND 1 AUG 2002, vol. 115, no. Pt 15, 1 August 2002 (2002-08-01), pages 3193 - 3206, XP002249135, ISSN: 0021-9533 *
JACOBS ET AL: "The oncogene and polycomb -group gene bmi - 1 regulates cell proliferation and senescence through the ink4a locus", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 397, no. 6715, 1999, pages 164 - 168, XP002144717, ISSN: 0028-0836 *
JACOBS JACQUELINE J L ET AL: "Cellular memory of transcriptional states by Polycomb-group proteins.", SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, vol. 10, no. 2, April 1999 (1999-04-01), pages 227 - 235, XP002249032, ISSN: 1084-9521 *
JAISWAL R K ET AL: "Adult human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by mitogen-activated protein kinase", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 275, no. 13, 31 March 2000 (2000-03-31), pages 9645 - 9652, XP002955257, ISSN: 0021-9258 *
JANDA ELZBIETA ET AL: "Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways.", THE JOURNAL OF CELL BIOLOGY. UNITED STATES 21 JAN 2002, vol. 156, no. 2, 21 January 2002 (2002-01-21), pages 299 - 313, XP002249134, ISSN: 0021-9525 *
KHANIM F ET AL: "Suppression of vitamin D3 signalling by aberrant histone deacetylation.", ANTI-CANCER DRUGS, vol. 13, no. 5, June 2002 (2002-06-01), First International Symposium on Vitamin D Analogs in Cancer Prevention and Therapy;Homburg/Saar, Germany; May 03-04, 2002, June, 2002, pages A4 - A5, XP009014430, ISSN: 0959-4973 *
KIM SONG-JA ET AL: "ERK-1/2 and p38 kinase oppositely regulate nitric oxide-induced apoptosis of chondrocytes in association with p53, caspase-3, and differentiation status.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 11 JAN 2002, vol. 277, no. 2, 11 January 2002 (2002-01-11), pages 1332 - 1339, XP002249133, ISSN: 0021-9258 *
LESSARD J ET AL: "FUNCTIONAL ANTAGONISM OF THE POLYCOMB-GROUP GENES EED AND BMI1 IN HEMOPOIETIC CELL PROLIFERATION", GENES AND DEVELOPMENT, COLD SPRING HARBOR LABORATORY PRESS, NEW YORK, US, vol. 13, no. 20, 15 October 1999 (1999-10-15), pages 2691 - 2703, XP000992904, ISSN: 0890-9369 *
LESSARD JULIE ET AL: "Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells.", NATURE. ENGLAND 15 MAY 2003, vol. 423, no. 6937, 20 April 2003 (2003-04-20), pages 255 - 260, XP002249033, ISSN: 0028-0836 *
LUDWIG S ET AL: "3pK, a novel mitogen-activated protein (MAP) kinase-activated protein kinase, is targeted by three MAP kinase pathways.", MOLECULAR AND CELLULAR BIOLOGY. UNITED STATES DEC 1996, vol. 16, no. 12, December 1996 (1996-12-01), pages 6687 - 6697, XP002249028, ISSN: 0270-7306 *
PRICE J ET AL: "NEURAL STEM CELLS", CURRENT OPINION IN NEUROBIOLOGY, LONDON, GB, vol. 11, 2001, pages 564 - 567, XP002952588, ISSN: 0959-4388 *
SERRANO M ET AL: "Putting the stress on senescence.", CURRENT OPINION IN CELL BIOLOGY. UNITED STATES DEC 2001, vol. 13, no. 6, December 2001 (2001-12-01), pages 748 - 753, XP002249031, ISSN: 0955-0674 *
VERMA AMIT ET AL: "Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 8 MAR 2002, vol. 277, no. 10, 8 March 2002 (2002-03-08), pages 7726 - 7735, XP002249027, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU2003227513A1 (en) 2003-11-11
DE10220480C1 (de) 2003-09-11
WO2003095633A2 (de) 2003-11-20
US20060094115A1 (en) 2006-05-04
EP1501920A2 (de) 2005-02-02

Similar Documents

Publication Publication Date Title
WO2007030743A3 (en) Cochlear implants containing biological cells and uses thereof
SG129236A1 (en) Somatic pluripotent cells
WO2008143704A3 (en) Engineered microorganisms for producing n-butanol and related methods
WO2008079469A3 (en) Genetically engineered biological indicator
MY170749A (en) Increasing methionine yield
WO2007055984A3 (en) Enzyme and methodology for the treatment of a biomass
HK1062331A1 (en) Magnetic sensor, production process of the magnetic sensor and magnetic array suitable for the production process
WO2002026941A3 (en) Primitive neural stem cells and method for differentiation of stem cells to neural cells
NO20053206D0 (no) Fremgangsmate for produsering av ketokarotenoider ved dyrking av genetisk modifiserte organismer.
WO2007005645A3 (en) Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
ATE475381T1 (de) Biologischer organerweiternder stent und herstellungsverfahren dafür
DE602004012881D1 (en) Cst (compartmentalised self tagging)
WO2002008388A3 (en) Stem cell-like cells
WO2006023136A3 (en) A neural stem cell-collagen-bioreactor system to construct a functional embryonic brain-like tissue
AU2003260404A1 (en) Process for producing and recovering mannosylerythritol lipids from culture medium containing the same
TW200642631A (en) Ergonomic support structure made of composite material for human body parts and method of manufacturing same
WO2004061458A3 (en) Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease
WO2007063545A3 (en) Methods of improving stem cell homing and engraftment
WO2004081533A3 (en) Vault and vault-like carrier molecules
EP1600498A4 (de) Hochdichte-zellanordnungsleiterplatte, prozess zum herstellen und verfahren zum verwenden derselben
WO2003006613A3 (en) Methods for ex vivo propagation of somatic stem cells
WO2003064630A3 (en) Cell culture medium
AU2003283409A1 (en) Method for generating a genetically modified organism for screening active substances
WO2007014544A3 (de) Stereoselektive synthese von chiralen diolen
WO2003095633A3 (de) Verfahren zur herstellung von zellen mit erhöhtem entwicklungspotential

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003724890

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003724890

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006094115

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10513500

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10513500

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003724890

Country of ref document: EP